Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection

Clinical trial NCT05027373 · UNKNOWN

Trial details

NCT number: NCT05027373
Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

Systemic Juvenile Idiopathic Arthritis Periodic Fever Syndrome

Start date: 2021-08-13
Primary completion: 2022-04-30
Enrollment: 34

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.